Up to 42% of anti-malaria drugs available across Southeast Asia and sub-Saharan Africa are poor quality or fake, resulting in drug resistance and inadequate treatment that threatens vulnerable populations and to undermine the huge progress made in recent years, according to a new study published online in The Lancet Infectious Diseases this week. The study was funded by the Fogarty International Center at the US National Institutes of Health in Bethesda, Maryland, where co-author Dr Joel Breman is Senior Scientist Emeritus...
More...
More...